Cited by 160Treatment of Major DepressionBipolar Disorder and TreatmentAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record.

Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy

Bodkin, J. Alexander, Lasser, Robert A., Wines, James D., Gardner, David M., Baldessarini, Ross J.·1997·The Journal of Clinical Psychiatry

DOI 10.4088/jcp.v58n0401

Open this paper in CoChat — free account

Abstract

BACKGROUND: Many patients with affective illness show partial or otherwise unsatisfactory responses to standard treatments, encouraging trials of combinations of pharmacologically dissimilar antidepressants. METHOD: Records of consecutive outpatients with affective disorders only partially responsive to treatment with a serotonin reuptake inhibitor (SRI) or bupropion, alone, were reviewed for changes in specific symptoms and risks of adverse events when an SRI and bupropion were combined. RESULTS: Greater symptomatic improvement was found in 19 (70%) of 27 subjects during a mean +/- SD of 11 +/- 14 months of combined daily use of bupropion (243 +/- 99 mg) with an SRI (31 +/- 16 mg fluoxetine-equivalents) than with either agent alone. Adverse effect risks were similar to those associated with each monotherapy, with a > 10% incidence of sexual dysfunction (N = 11, 41%), insomnia (N = 6, 22%), anergy (N = 4, 15%), and tremor (N = 3, 11%) during combined therapy; there were no seizures. CONCLUSION: With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy.

Integrity signals

Registry

Crossref · 10.4088/jcp.v58n0401

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
Effects of SSRIs on Sexual Function
Rosen, R. C., Lane, R. M., & Menza, M. A. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 654
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 569
Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study
D, M. F. M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeïm, H. A., Quitkin, F. M., Wisniewski, S. R., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 528
A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants
Hesse, L. M., Venkatakrishnan, K., Court, M. H., Moltke, L. L., Duan, S., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 398
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
The many faces of fatigue in major depressive disorder
Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004729 · Cited by 288
15 Years of Clinical Experience With Bupropion HCl
D, M. F. M., Rush, A. J., Thase, M. E., Clayton, A. H., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 261
Anhedonia and Substance Dependence: Clinical Correlates and Treatment Options
Hatzigiakoumis, D. S., Martinotti, G., Giannantonio, M. D., & Janiri, L. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00010 · Cited by 245
Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression
Yoshimura, R., Hori, H., Ikenouchi, A., Umene‐Nakano, W., Ueda, N., & Nakamura, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.03.020 · Cited by 232
Depression and sexual dysfunction
Baldwin, D. S. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.81 · Cited by 217
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.
Stahl, S. M., Zhang, L., Damatarca, C., & Grady, M. M. (2003) · PubMed · Cited by 202
Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?
Clayton, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.457 · Cited by 187
Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
Cao, B., Zhu, J., Zuckerman, H., Rosenblat, J. D., Brietzke, E., Pan, Z., Subramanieapillai, M., Park, C., Lee, Y., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.002 · Cited by 175
Choices in Antipsychotic Therapy in Schizophrenia
Frankenburg, F. R. (1999) · Harvard Review of Psychiatry · doi:10.3109/10673229909000336 · Cited by 170
Dopaminergic-based pharmacotherapies for depression
Papakostas, G. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.002 · Cited by 171
Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats
Li, S. X.-M., Perry, K. W., & Wong, D. T. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00160-5 · Cited by 156
Sexual side-effects of antidepressant and antipsychotic drugs
Baldwin, D. S., & Mayers, A. (2003) · Advances in Psychiatric Treatment · doi:10.1192/apt.9.3.202 · Cited by 155
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
D, M. F. M., & Rush, A. J. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091771 · Cited by 151
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation
Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., Turkoz, I., Lasser, R. A., Loescher, A., Bouhours, P., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301113 · Cited by 149
Self-citation
Assessing the effects of bupropion SR on mood dimensions of depression
Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S., & Shelton, R. C. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00306-3 · Cited by 139
Augmentation and combination strategies in treatment-resistant depression.
D, M. F. M. (2001) · PubMed · Cited by 141
Use of Bupropion in Combination with Serotonin Reuptake Inhibitors
Zisook, S., Rush, A. J., Haight, B. R., Clines, D. C., & Rockett, C. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.027 · Cited by 140
Can Recovery From Depression Be Achieved?
Shelton, R. C., & Tomarken, A. J. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1469 · Cited by 111
Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor
Skolnick, P., Krieter, P. A., Tizzano, J. P., Basile, A. S., Popik, P., Czobor, P., & LIPPA, A. S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00123.x · Cited by 107
Pharmacological and Psychological Treatments for Depressed Older Patients: A Meta-analysis and Overview of Recent Findings
Gerson, S. C., Belin, T. R., Kaufman, A., Mintz, J., & Jarvik, L. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.1.1 · Cited by 99
Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases
Alam, M., Ali, S., Ahmed, S., Elasbali, A. M., Adnan, M., Islam, A., Hassan, M. I., & Yadav, D. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212162 · Cited by 91
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., de Filippis, R., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 94
Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
Guiard, B. P., Mansari, M. E., & Blier, P. (2009) · Current Drug Targets · doi:10.2174/138945009789735156 · Cited by 99
Evaluation of Sexual Functioning in Depressed Outpatients: A Double-Blind Comparison of Sustained-Release Bupropion and Sertraline Treatment
Segraves, R. T., Kavoussi, R. J., Hughes, A. R., Batey, S. R., Johnston, J. A., Donahue, R. M. J., & Ascher, J. A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00002 · Cited by 90
Citalopram and Bupropion-SR
Lam, R. W. M., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Strategies for the treatment of antidepressant-related sexual dysfunction.
Zajecka, J. (2001) · PubMed · Cited by 86
A Prospective Trial of Bupropion SR Augmentation of Partial and Non-Responders to Serotonergic Antidepressants
DeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Schatzberg, A. F. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00005 · Cited by 83
Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians
Mischoulon, D., Nierenberg, A. A., Kizilbash, L., Rosenbaum, J. F., & D, M. F. M. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500509 · Cited by 81
TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design
Trivedi, M. H., Greer, T. L., Grannemann, B. D., Church, T. S., Galper, D. I., Sunderajan, P., Wisniewski, S. R., Chambliss, H., JORDAN, A. N., Finley, C. E., et al. (2006) · Clinical Trials · doi:10.1191/1740774506cn151oa · Cited by 81
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence
Thase, M. E. (2004) · CNS Spectrums · doi:10.1017/s1092852900002236 · Cited by 66
Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases
Ramos-Hryb, A. B., Pazini, F. L., Kaster, M. P., & Rodrigues, A. L. S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0474-4 · Cited by 66
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
Papakostas, G. I., Worthington, J. J., Iosifescu, D. V., Kinrys, G., Burns, A. M., Fisher, L. B., Homberger, C. H., Mischoulon, D., & D, M. F. M. (2006) · Depression and Anxiety · doi:10.1002/da.20181 · Cited by 61
Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Marks, D., Pae, C., & Patkar, A. A. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386078 · Cited by 61
Progression of Subcortical Ischemic Disease From Vascular Depression to Vascular Dementia
Steffens, D. C., Taylor, W. D., & Krishnan, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.10.1751 · Cited by 54
Combination/augmentation strategies for improving the treatment of depression
Moret, C. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a798 · Cited by 54
Psychopharmacologic Treatments for Nonparaphilic Compulsive Sexual Behaviors
Kafka, M. P. (2000) · CNS Spectrums · doi:10.1017/s1092852900012669 · Cited by 51
Mood and metabolism: Anhedonia as a clinical target in Type 2 diabetes
Carter, J., & Swardfager, W. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.04.002 · Cited by 56
Pramipexole Augmentation of a Selective Serotonin Reuptake Inhibitor in the Treatment of Depression
DeBattista, C., Solvason, H. B., Breen, J. A. H., & Schatzberg, A. F. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00029 · Cited by 48
Combined antidepressants: clinical experience
Rojo, E., Ros, S., Agüera, L., de la Gándara, J., & de Pedro, J. M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00677.x · Cited by 48
Augmentation and combination strategies for depression
DeBattista, C. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806064310 · Cited by 47
A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression
Nierenberg, A. A., Katz, J., & D, M. F. M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.001 · Cited by 48
Topiramate Abuse in a Bipolar Patient With an Eating Disorder
Colom, F., Vieta, E., Benabarre, A., Martínez‐Arán, A., Reinares, M., Corbella, B., & Gastó, C. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612c · Cited by 47
Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder
Soskin, D. P., Carl, J. R., Alpert, J. E., & D, M. F. M. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00318.x · Cited by 46
PHARMACOLOGIC TREATMENT FOR CHILDREN AND ADOLESCENTS WITH ANXIETY DISORDERS
Birmaher, B. B., Yelovich, A. K., & Renaud, J. (1998) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70069-9 · Cited by 45
An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder
Leuchter, A. F., Lesser, I. M., Trivedi, M. H., Rush, A. J., Morris, D. W., Warden, D., D, M. F. M., Wisniewski, S. R., Luther, J. F., Perales, M. L., et al. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000336754.19566.65 · Cited by 46
Medical management of obesity associated with mental disorders.
Malhotra, S., & McElroy, S. L. (2002) · PubMed · Cited by 44
Further SAR Studies of Piperidine-Based Analogues of Cocaine. 2. Potent Dopamine and Serotonin Reuptake Inhibitors
Tamiz, A. P., Zhang, J., Flippen-Anderson, J. L., Zhang, M., Johnson, K. M., Deschaux, O., Tella, S. R., & Kozikowski, A. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9905561 · Cited by 44
An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.
Barowsky, J., & Schwartz, T. L. (2006) · PubMed Central · Cited by 39
Switching to Bupropion in Fluoxetine-Resistant Major Depressive Disorder
D, M. F. M., Papakostas, G., Petersen, T., Mahal, Y., Quitkin, F., Stewart, J., & McGrath, P. (2003) · Annals of Clinical Psychiatry · doi:10.1023/a:1023224525400 · Cited by 41
Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression
Devadoss, T., Pandey, D. K., Mahesh, R., & Yadav, S. K. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70263-2 · Cited by 38
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 41
Reboxetine adjunct for partial or nonresponders to antidepressant treatment
Rubio, G., San, L., Lopez-Munoz, F. J., & Álamo, C. (2003) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.08.001 · Cited by 38
Are There Differences in the Symptoms that Respond to a Selective Serotonin or Norepinephrine Reuptake Inhibitor?
Nelson, J. C., S, L. P. M., & Leon, A. C. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.030 · Cited by 36
Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677
Popik, P., Krawczyk, M., Gołembiowska, K., Nowak, G., Janowsky, A. J., Skolnick, P., LIPPA, A. S., & Basile, A. S. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9012-5 · Cited by 35
Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial
Morris, D. W., Budhwar, N., Husain, M. M., Wisniewski, S. R., Kurian, B. T., Luther, J., Kerber, K. A., Rush, A. J., & Trivedi, M. H. (2012) · The Annals of Family Medicine · doi:10.1370/afm.1316 · Cited by 32
Assessment of Sexual Dysfunction Using the Arizona Sexual Experiences Scale (ASEX) and Implications for the Treatment of Depression
McGahuey, C. A., Delgado, P. L., & Gelenberg, A. J. (1999) · Psychiatric Annals · doi:10.3928/0048-5713-19990101-10 · Cited by 32
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Dichter, G. S., Tomarken, A. J., Freid, C. M., Addington, S., & Shelton, R. C. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.10.007 · Cited by 31
What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder.
Zamorski, M. A., & Albucher, R. C. (2002) · PubMed · Cited by 30
ANTIDEPRESSANT AUGMENTATION AND COMBINATIONS
Dording, C. M. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70195-7 · Cited by 29
Treatment of Depression in Children and Adolescents
Bostic, J. Q., Rubin, D. H., Prince, J. B., & Schlozman, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200505000-00002 · Cited by 28
Triple Reuptake Inhibitors: A Premise and Promise
Marks, D. M., Pae, C., & Patkar, A. A. (2008) · Psychiatry Investigation · doi:10.4306/pi.2008.5.3.142 · Cited by 26
Venlafaxine and Bupropion Combination Therapy in a Case of Treatment-Resistant Depression
Fatemi, S. H., Emamian, E. S., & Kist, D. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18249 · Cited by 27
Managing Treatment-Emergent Sexual Dysfunction Associated with Serotonergic Antidepressants: Before and After Sildenafil
Nurnberg, H. G. (2001) · Journal of Psychiatric Practice · doi:10.1097/00131746-200103000-00003 · Cited by 26
Internet-Observed Suicide Attempts
Janson, M. P., Alessandrini, E. S., Strunjas, S. S., Shahab, H., El‐Mallakh, R. S., & Lippmann, S. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612f · Cited by 24
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials
Learned, S. M., Graff, O. X., Roychowdhury, S. M., Moate, R., Krishnan, K., Archer, G. E., Modell, J. G., Alexander, R., Zamuner, S., Lavergne, A., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424931 · Cited by 23
Therapieresistenz auf Antidepressiva
Møller, H. J. (2004) · Der Nervenarzt · doi:10.1007/s00115-004-1728-1 · Cited by 23
Tianeptine combination for partial or non‐response to selective serotonin re‐uptake inhibitor monotherapy
Woo, Y. S., Bahk, W., Jeong, J., Lee, S., Sung, H., Pae, C., Koo, B., & Kim, W. K. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12042 · Cited by 22
Augmentation of standard depression therapy
Marangell, L. B. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80071-5 · Cited by 21
Sildenafil in the Treatment of Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors
Nurnberg, H. G., Hensley, P. L., & Lauriello, J. (2000) · CNS Drugs · doi:10.2165/00023210-200013050-00003 · Cited by 21
Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline
Yoshimura, R., Umene‐Nakano, W., Ueda, N., Ikenouchi, A., Hori, H., & Nakamura, J. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.979 · Cited by 20
Clinical Pharmacology and Therapeutics of Antidepressants
Ciraulo, D. A., Tsirulnik-Barts, L., Shader, R. I., & Greenblatt, D. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-792-5_2 · Cited by 20
Dopamine and Depression
Skolnick, P. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_9 · Cited by 20
Using semantic analysis of texts for the identification of drugs with similar therapeutic effects
Tutubalina, E. V., Miftahutdinov, Z., Ирекович, Н. Р., Madzhidov, T., Nikolenko, S., Alimova, I., & Tropsha, A. (2017) · Russian Chemical Bulletin · doi:10.1007/s11172-017-2000-8 · Cited by 20
Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression
Axford, L. C., Boot, J. R., Hotten, T. M., Keenan, M., Martin, F. M., Milutinovic, S., Moore, N. A., O‘Neill, M. F., Pullar, I. A., Tupper, D. E., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00660-7 · Cited by 19
Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study
Bae, K., Kim, S., Kim, J. M., Shin, I., Yoon, J., Jung, S.-W., Lee, M., Yim, H. W., & Jun, T. (2011) · Psychiatry Investigation · doi:10.4306/pi.2011.8.3.234 · Cited by 18
DEPRESSIVE BREAKTHROUGH
Nierenberg, A. A., & Alpert, J. E. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70194-5 · Cited by 18
Anhedonia: Current and future treatments
Serretti, A. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70088 · Cited by 26
Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression?
Stewart, J. W., McGrath, P. J., Deliyannides, R. A., & Quitkin, F. M. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000361276.88339.44 · Cited by 17
Clinical Pharmacology and Therapeuticsof Antidepressants
Ciraulo, D. A., Shader, R. I., & Greenblatt, D. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_2 · Cited by 17
NEW DRUGS IN PSYCHIATRY
Goldberg, J. F. (2000) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(05)70119-x · Cited by 15
Treatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000351880.30013.2a · Cited by 15
The Many Uses of Bupropion and Bupropion Sustained Release (SR) in Adults
Berigan, T. R. (2002) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v04n0110a · Cited by 15
ASHP Therapeutic Position Statement on the Recognition and Treatment of Depression in Older Adults
Semla, T. P., & Watanabe, M. D. (1998) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/55.23.2514 · Cited by 15
Gabapentin for the Treatment of Patients With Somatization Disorder
García‐Campayo, J., & Sanz-Carrillo, C. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612a · Cited by 15
Strategies for Augmentation of SSRI Treatment: A Survey of an Academic Psychopharmacology Practice
Mischoulon, D., D, M. F. M., & Rosenbaum, J. F. (1999) · Harvard Review of Psychiatry · doi:10.3109/10673229909017210 · Cited by 15
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836
Zheng, M., Appel, L., Luo, F. R., Lane, R. M., Burt, D. A., Risinger, R. C., Antoni, G., Cahir, M., Keswani, S. C., Hayes, W., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3688-x · Cited by 12
"I See Dead People": Overcoming Psychic Numbness
Brendel, D. H., Bodkin, J. A., Hauptman, B., & Ornstein, A. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216216 · Cited by 12
Self-citation
Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study
Seguı́, J., Lopez-Munoz, F. J., Álamo, C., Camarasa, X., García, P. G., & Pardo, A. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102641 · Cited by 12

Authors: Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J.
Affiliations: Harvard University (US)
ORCID: Gardner, David M.
Baldessarini, Ross J.
Venue: The Journal of Clinical Psychiatry
Publisher: Physicians Postgraduate Press, Inc
Published: 1997-04-15
Volume: 58
Issue: 4
Pages: 137-145
ISSN: 0160-6689 (ISSN-L)
DOI: 10.4088/jcp.v58n0401
OpenAlex: W1982954842
Cited by: 159
References: 0
Citations by year: 2026: 1 · 2025: 1 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 4 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 6
FWCI: 7.60
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k05mh047370-25)
National Institute of Mental Health (P01MH031154, MH-31154, MH47370)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: serotonin reuptake inhibitors, bupropion, antidepressant combination therapy, antidepressant monotherapy, mood disorders, adverse drug reactions, sexual dysfunction, insomnia, anergia, tremor, seizure risk
MeSH terms: Adult, Aged, Ambulatory Care, Anxiety Disorders, Depressive Disorder, Drug Administration Schedule, Drug Therapy, Combination, Epilepsy, Female, Fluoxetine, Humans, Male, Middle Aged, 1-Naphthylamine, Panic Disorder, Bupropion, Fluvoxamine, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Dysthymic Disorder, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks